Figure 3 from Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

2026 Open access

Read full text
Authors: Robert L. Hollis, Austin Miller, Heather A. Lankes, Kwong‐Kwok Wong, William Rodgers, David W. M. Millan, Karen Carty, Robert Louis Coleman, Kathleen N. Moore, Angeles Alvarez Secord, David M. O’Malley, John K. Chan
+13 more Andrea R. Hagemann, Stephanie L. Gaillard, Saketh R. Guntupalli, Mitchell I. Edelson, Peter Graham Rose, Oliver Dorigo, Susana N. Banerjee, Ailith Ewing, Michael Churchman, Anil K. Sood, C. Simon Herrington, Charlie Gourley, David Marc Gershenson
DOI: 10.1158/1078-0432.31353247
Cited by: 0

Abstract

Impact of pERK status and KRAS/BRAF/NRAS mutation status on GOG281 patient outcome. A, PFS of GOG281/LOGS patients with low-pERK tumors (pERK ≤ 140) in trametinib versus SOC arms. B, PFS of GOG281/LOGS patients with high-pERK tumors (pERK > 140) in trametinib versus SOC arms. C, PFS of GOG281/LOGS patients with KRAS/BRAF/NRAS WT tumors in trametinib versus SOC arms. D, PFS of GOG281/LOGS patients with KRAS/BRAF/NRAS-mutant tumors in trametinib versus SOC arms. Labeled HR refer to comparison of trametinib versus SOC arm.

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment BRCA gene mutations in cancer Ovarian function and disorders

Publication details

Publication date
17 February 2026
Language
EN